Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for UroGen Pharma (URGN) over the last 3 years, with Q2 2021 value amounting to $232000.0.

  • UroGen Pharma's Amortization of Deferred Charges fell 3878.63% to $232000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $1.3 million, marking a year-over-year increase of 418.6%. This contributed to the annual value of $1.6 million for FY2020, which is 5836.58% up from last year.
  • As of Q2 2021, UroGen Pharma's Amortization of Deferred Charges stood at $232000.0, which was down 3878.63% from $237000.0 recorded in Q1 2021.
  • In the past 5 years, UroGen Pharma's Amortization of Deferred Charges registered a high of $494000.0 during Q4 2020, and its lowest value of $232000.0 during Q2 2021.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $269000.0 (2019), whereas its average is $312500.0.
  • In the last 5 years, UroGen Pharma's Amortization of Deferred Charges skyrocketed by 6917.81% in 2020 and then crashed by 3878.63% in 2021.
  • Quarter analysis of 3 years shows UroGen Pharma's Amortization of Deferred Charges stood at $292000.0 in 2019, then skyrocketed by 69.18% to $494000.0 in 2020, then crashed by 53.04% to $232000.0 in 2021.
  • Its Amortization of Deferred Charges was $232000.0 in Q2 2021, compared to $237000.0 in Q1 2021 and $494000.0 in Q4 2020.